Intrexon Corporation (NYSE:XON) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 11,979 call options on the stock. This represents an increase of Infinity compared to the average daily volume of 0 call options.
In other Intrexon Corporation news, Director Robert B. Shapiro acquired 2,850 shares of Intrexon Corporation stock in a transaction that occurred on Tuesday, August 22nd. The stock was bought at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the acquisition, the director now owns 43,157 shares of the company’s stock, valued at $755,247.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 55.10% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Intrexon Corporation by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock valued at $106,811,000 after buying an additional 147,517 shares in the last quarter. State Street Corp raised its stake in Intrexon Corporation by 34.0% during the 1st quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock valued at $53,664,000 after purchasing an additional 687,406 shares during the period. First Trust Advisors LP raised its stake in Intrexon Corporation by 3.4% during the 3rd quarter. First Trust Advisors LP now owns 1,588,779 shares of the biotechnology company’s stock valued at $30,203,000 after purchasing an additional 51,691 shares during the period. Peregrine Capital Management LLC raised its stake in Intrexon Corporation by 25.3% during the 3rd quarter. Peregrine Capital Management LLC now owns 583,328 shares of the biotechnology company’s stock valued at $11,089,000 after purchasing an additional 117,605 shares during the period. Finally, Geode Capital Management LLC raised its stake in Intrexon Corporation by 3.5% during the 1st quarter. Geode Capital Management LLC now owns 429,532 shares of the biotechnology company’s stock valued at $8,513,000 after purchasing an additional 14,674 shares during the period. 77.28% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently commented on XON shares. Northland Securities reiterated a “buy” rating and issued a $27.00 price objective on shares of Intrexon Corporation in a report on Friday, October 6th. BidaskClub cut Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Bank of America Corporation dropped their target price on Intrexon Corporation from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Griffin Securities reissued a “buy” rating and issued a $55.00 target price on shares of Intrexon Corporation in a research report on Friday, October 6th. Finally, JMP Securities reissued an “outperform” rating and issued a $42.00 target price on shares of Intrexon Corporation in a research report on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Intrexon Corporation presently has a consensus rating of “Hold” and a consensus price target of $38.50.
Intrexon Corporation (NYSE XON) opened at $13.62 on Friday. Intrexon Corporation has a 12-month low of $10.26 and a 12-month high of $31.85. The company has a current ratio of 2.05, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01.
TRADEMARK VIOLATION WARNING: This article was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://ledgergazette.com/2017/11/17/stock-traders-buy-high-volume-of-intrexon-corporation-call-options-xon.html.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.